Comparing Transvaginal Self-tailored Titanium-coated Polypropylene Mesh Procedure With Mesh-kit Procedure.

March 4, 2019 updated by: Peking Union Medical College Hospital

A Multicenter Randomized Controlled Non-inferiority Trial Comparing Transvaginal Self-tailored Titanium-coated Polypropylene Mesh Procedure With Mesh-kit Procedure.

Pelvic organ prolapse(POP) is a common health problem and has significant negative effects on woman's quality of life. Transvaginal mesh procedure is a durable reconstructive surgery, but the mesh kits are expensive for underdeveloped countries. Our preliminary trial showed that the use of self-tailored mesh had good success rate (91.8% at 1-year follow-up) and low complication rate. The trial is designed to compare self-tailored titanium-coated polypropylene mesh procedure with mesh-kit in the treatment of POP stage III-IV in terms of efficacy, safety and cost-effective .

Study Overview

Status

Unknown

Detailed Description

The trial is a randomized controlled multi-center non-inferiority trial. The primary outcome measure is success rate at 1-year follow-up. The second outcomes are subjective improvement of quality of life, complications and costs. Analysis will be performed according to the intention to treat principle. Based on comparable success rate of 90% and 10% as the margin(beta 0.2 and one sided alpha 0.025), about 312 patients in total from 11 centers will be recruited per group including 10% drop-out. The aims of the research are to demonstrate whether self-tailored mesh is non-inferior to the mesh-kit. The finding of this research might influence the treatment selection for POP in China.

Study Type

Interventional

Enrollment (Anticipated)

312

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Beijing
      • Beijing, Beijing, China
        • Recruiting
        • Peking Union Medical College Hospital
    • Guangdong
      • Foshan, Guangdong, China
        • Recruiting
        • Fosha Maternal and Child Health Care Hospital
      • Guangzhou, Guangdong, China
        • Recruiting
        • The First Affiliated Hospital of Guangzhou Medical College
    • Hunan
      • Changsha, Hunan, China
        • Recruiting
        • The Second Xiangya Hospital of Central South University
      • Changsha, Hunan, China
        • Recruiting
        • Changsha Maternal and Child Health Care Hospital
    • Jiangsu
      • Wuxi, Jiangsu, China
        • Recruiting
        • Wuxi Maternal and Child Health Care Hospital
    • Shandong
      • Jinan, Shandong, China
        • Recruiting
        • Qilu Hospital of Shandong University
    • Shanxi
      • Xi'an, Shanxi, China
        • Recruiting
        • Shanxi Provincial People's Hospital
    • Sichuan
      • Chengdu, Sichuan, China
        • Recruiting
        • Sichuan University West China Second University Hospital
    • Xinjiang
      • Ürümqi, Xinjiang, China
        • Recruiting
        • The First Affiliated Hospital of Xinjiang Medical University
      • Ürümqi, Xinjiang, China
        • Recruiting
        • The People's hospital of Xinjiang Uygur Autonomous Region

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Age:More than 50 years old with 3 years after menopause or more than 55 years old, but less than 75 years old.
  • Subject must have severe apical or anterior vaginal prolapse (stage III-IV), with moderate posterior vaginal prolapse(stage I-II). This is defined as ( C > +1cm OR Ba > +1cm, with Bp ≤+1cm by the POP-Q). This is the most common modality of multiple compartment POP in clinic.
  • Subject reports a bothersome bulge they can see or feel per PFDI-20, question 3, response of 2 or higher (i.e., responses of "somewhat", "moderately", or "quite a bit").
  • Desires transvaginal mesh treatment for primary or recurrent, symptomatic uterovaginal prolapse.
  • Concomitant hysterectomy when indicated. But concomitant anti-incontinence surgeries will not be enrolled.
  • Subject is willing and able to comply with the follow-up regimen.

Exclusion Criteria:

  • Subject is pregnant or intends to become pregnant in the future
  • Subject has an active or chronic systemic infection including any gynecologic infection, untreated urinary tract infection (UTI) or tissue necrosis
  • Subject has history of pelvic organ cancer (e.g. uterine, ovarian, bladder, colo-rectal or cervical)
  • Subject has had prior or is currently undergoing radiation, laser therapy, or chemotherapy in the pelvic area
  • Subject has taken systemic steroids (within the last month), or immunosuppressive or immunomodulatory treatment (within the last 3 months)
  • Subject has systemic connective tissue disease (e.g. scleroderma, systemic lupus erythematosus (SLE), Marfan syndrome, Ehlers Danlos, collagenosis, polymyositis, polymyalgia rheumatica)
  • Subject has chronic systemic pain that includes the pelvic area or chronic focal pain that involves the pelvis
  • Subject has uncontrolled diabetes mellitus (DM)
  • Subject has a known neurologic or medical condition affecting bladder function (e.g., multiple sclerosis, spinal cord injury or stroke with residual neurologic deficit)
  • Subject has had previous prolapse repair with mesh in the target compartment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: self-cut mesh procedure
This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
transvaginal mesh implantation for pelvic organ prolapse
Active Comparator: mesh-kit procedure
This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
transvaginal mesh implantation for pelvic organ prolapse

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
surgical "success"
Time Frame: up to 36 months after operation

Subjects will be considered a success if they meet the definitions of anatomic cure and deny vaginal bulging symptoms, and no additional treatment for prolapse(surgical or pessary use).

Anatomic cure is defined as leading edge above the hymen (i.e Ba, C, Bp<0 cm) Symptomatic cure is defined as the absence of vaginal bulge symptoms as indicated by a negative response question 3 of the pelvic floor distress inventory- 20 (PFDI-20): "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?

up to 36 months after operation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
intraoperative and post operative complications
Time Frame: up to 36 months after operation
using IUGA/ICS joint terminology CTS coding system and dingo system
up to 36 months after operation
anatomic outcomes
Time Frame: up to 36 months after operation
anatomic outcome of each vaginal segment( anterior, posterior and apical) using POP-Q score.
up to 36 months after operation
symptomatic improvement using validated instruments(PFIQ-7)
Time Frame: up to 36 months after operation
Relief of symptoms using validated instruments(PFIQ-7) .
up to 36 months after operation
symptomatic improvement using validated instruments(PFDI-20)
Time Frame: up to 36 months after operation
Relief of symptoms using validated instruments(PFDI-20) .
up to 36 months after operation
symptomatic improvement using validated instruments(PISQ-12)
Time Frame: up to 36 months after operation
Relief of symptoms using validated instruments(PISQ-12)
up to 36 months after operation
symptomatic improvement using patient global impression of change (PGI-C)
Time Frame: up to 36 months after operation
Relief of symptoms using patient global impression of change (PGI-C)
up to 36 months after operation
post operative pain
Time Frame: within 3 days after operation
visual analogue scales (VAS) were used to evaluate the degree of pain.
within 3 days after operation
Hospital costs
Time Frame: up to 4 weeks after operation
hospitlization expenses
up to 4 weeks after operation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 12, 2018

Primary Completion (Anticipated)

January 12, 2020

Study Completion (Anticipated)

January 12, 2022

Study Registration Dates

First Submitted

May 7, 2017

First Submitted That Met QC Criteria

September 12, 2017

First Posted (Actual)

September 14, 2017

Study Record Updates

Last Update Posted (Actual)

March 5, 2019

Last Update Submitted That Met QC Criteria

March 4, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • self-cut mesh vs mesh-kit

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pelvic Organ Prolapse

Clinical Trials on pelvic floor reconstructive surgery

3
Subscribe